FUJIFILM Irvine Scientific, a company developing and manufacturing serum-free and chemically-defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, recently announced it will purchase Warminster-based Shenandoah Biotechnology for an undisclosed amount.
Shenandoah Biotechnology produces recombinant proteins, a material used in various life science applications, including cell therapy, gene therapy, and regenerative medicine. The company manufactures cytokines and growth factors, among other recombinant proteins.
The purchase will allow FUJIFILM Irvine Scientific, a division of FUJIFILM Corp., to position itself in the rapidly-growing advanced therapy market. The company said Shenandoah Biotechnology’s portfolio of recombinant proteins complements FUJIFILM’s advanced cell culture solutions and expertise in bioprocessing.
The purchase is expected to help FUJIFILM’s Life Sciences Business to reach its sales target of $850 million by fiscal year 2025.
“At Shenandoah Biotechnology, our vision is to provide a superior and affordable source of recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets,” Pamela De Lacy, Shenandoah Biotechnology president, said. “We are pleased to join FUJIFILM Irvine Scientific given their experience with manufacturing ancillary materials for cell and gene therapy and commitment to providing high quality products and service to customers.”
The deal is expected to close by April.